In the context of transforming the national health system, especially the pillar of transforming the health resilience system, the Ministry of Health is making efforts to increase the resilience of the pharmaceutical sector. There are 4 pillars of pharmaceutical preparations that are encouraged to increase production in the country, namely chemical active pharmaceutical ingredients (API), vaccines, biopharmaceuticals, and naturals.

Indonesia has about 143 million hectares of tropical forest, estimated to have 28 thousand plant species. Indonesia is also home to 80% of the world's medicinal plants that have the potential to be utilized, especially in the development of traditional medicine and reducing import dependence. One of the pharmaceutical sector's resilience strategies is the development of herbal medicine and OHT into phytopharmaceuticals based on therapeutic areas and the availability of natural ingredients. Phytopharmaca is a product based on natural ingredients that has been clinically tested and the raw materials used and the products produced are standardized.

In an effort to follow up and synergize steps in accelerating the development of phytopharmaca products, Dit. Pharmaceutical and Health Security held an ABGCI Coordination FGD to Accelerate Product Development and Increase Phytopharmaceutical Competitiveness on Tuesday, June 21, 2022, attended by 65 offline participants consisting of industries that have and will develop phytopharmaceutical products, participants from the Ministry of Health, BPOM, BRIN, Universities, Associations (GP Jamu) and online participants, namely industries that have and will develop phytopharmaceutical products and universities outside Jakarta.

In his report, the Head of the Working Team for Development and Facilitation of Downstreaming of Raw Materials and Preparations of Phytopharmaca and Domestic Biological Products Refiandes said that this activity aims to map the latest progress of phytopharmaca product development in Indonesia, identify problems in phytopharmaca product development in Indonesia and provide recommendations for accelerating product development and increasing phytopharmaca competitiveness to be carried out by stakeholders related to efforts to accelerate product development and increase phytopharmaca competitiveness.

Director General of Pharmaceuticals and Medical Devices L. Rizka Andalucia, had the opportunity to give directions as well as officially open this activity. The Director General said that Indonesia's high biodiversity is a potential so it is hoped that phytopharmaca raw materials should be produced locally. "My hope is that we can produce natural raw materials independently in the country because we have a lot of potential," said the Director General. The Director General also said that related to the development of phytopharmaca products, there are 3 key points that must be done, namely: Increasing demand for Increasing demand for phytopharmaceuticals; Increasing production and procurement of phytopharmaceuticals and Increasing research on traditional medicines and phytopharmaceuticals. Efforts to accelerate the development and increase the competitiveness of phytopharmaceutical products require the cooperation of all parties from the Government, Academia/Research Institutions, Industry and the Community. Strengthening regulations, research, improving human resource competencies, providing incentives for industry and close coordination and synergy are needed in this effort.